VXRT:OTCMKTS
Vaxart Inc
0,43 USD
arrow_downward
-0,02%(-0,000075) 1D
9-окт., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for VXRT...
Open
0,44 USD
High
0,45 USD
Low
0,43 USD
Mkt. cap
106,59 млн
Avg. vol.
265,13 миң
Volume
198,22 миң
P/E ratio
2,66
52-wk high
0,84 USD
52-wk low
0,30 USD
EPS
0,16 USD
Beta
1,05
Shares outstanding
242,84 млн
No. of employees
65
Open
0,44 USD
High
0,45 USD
Low
0,43 USD
Mkt. cap
106,59 млн
Avg. vol.
265,13 миң
Volume
198,22 миң
P/E ratio
2,66
52-wk high
0,84 USD
52-wk low
0,30 USD
EPS
0,16 USD
Beta
1,05
Shares outstanding
242,84 млн
No. of employees
65
News stories
From web sources and news partners
Simply Wall Street
·
2 мүнөт мурун
Does Advanced Micro Devices (AMD) Face New AI Demand Risk After A Customer Reset?
Barchart.com
·
1 саат мурун
The S&P 500 Is Near Record Highs. So Why Does Your Portfolio Feel Like a Bear Market?
FXLeaders
·
28 мүнөт мурун
Dow Jones and Nasdaq Futures Start Higher Ahead of US Inflation Data
24/7 Wall St.
·
9 саат мурун
KLA Turned $1,000 Into $31,595 in a Decade, Crushing the S&P 500 by 8.7x
Profile
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
About Vaxart Inc
CEO-
Employees65
Foundedмар. 2004
HeadquartersЮг Сан Франциско, Калифорния, Америка Кошмо Штаттары
Sector-
Websitevaxart.com